RESUMEN
Risk factors associated with the development of aGVHD in the gastrointestinal tract have not been studied in depth. We retrospectively assessed 25 pediatric patients with MDS and JMML and compared the treatment outcome of two different conditioning regimens. Seventeen children (68%) underwent conditioning with busulfan (Bu), cyclophosphamide (Cy), and melphalan (Mel) and eight children (32%) with Bu and Cy. Gastrointestinal aGVHD stages II-IV (day 0-100) were observed in 47% (eight of 17) of the patients in the BuCyMel group and in none (0 of 8) in the BuCy group (p < 0.05). In patients who developed gastrointestinal aGVHD stages III-IV, a 24-h variation in the Bu concentration with a nighttime peak was noted. HC and liver aGVHD stages II-IV were observed in 47% (eight of 17) and 35% (six of 17) after BuCyMel conditioning and in 0% (0 of 17) and 12.5% (one of eight) after BuCy conditioning. The overall survival rate was 53% (nine of 17) in the BuCyMel group and 62.5% (five of eight) in the BuCy group. In conclusion, the addition of melphalan to the BuCy conditioning regimen resulted in severe gastrointestinal complications and did not improve overall survival.
Asunto(s)
Busulfano/efectos adversos , Ciclofosfamida/efectos adversos , Enfermedad Injerto contra Huésped/diagnóstico , Melfalán/efectos adversos , Acondicionamiento Pretrasplante/efectos adversos , Adolescente , Busulfano/administración & dosificación , Niño , Preescolar , Femenino , Tracto Gastrointestinal/efectos de los fármacos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Lactante , Leucemia Mielomonocítica Aguda/terapia , Masculino , Melfalán/administración & dosificación , Síndromes Mielodisplásicos/terapia , Estudios Retrospectivos , Factores de Riesgo , Acondicionamiento Pretrasplante/métodos , Resultado del TratamientoRESUMEN
AIM: To evaluate two simplified Helicobacter pylori eradication treatment alternatives for children and adolescents. METHODS: Study subjects were identified by enzyme-linked immunosorbent assay and immunoblot in a family screening project. Helicobacter pylori infected 10-21 year olds were offered treatment, individuals with abdominal pain underwent upper endoscopy and those with peptic ulcers were excluded. Participants were randomized to either azithromycin 500 mg daily and tinidazole 500 mg two tablets daily in combination with lansoprasole 30 mg daily for 6 days (ATL-group) or with placebo (ATP-group). Urea Breath Test was performed at inclusion and after a minimum of 6 weeks after end of therapy. RESULTS: In total, 131 individuals were randomized, of whom 31 (24%) had undergone upper endoscopy. Full compliance was achieved in 93% (122 of 131). The intention-to-treat eradication rate was 67% (44 of 66) and 58% (38 of 65) for the ATL- and the ATP-group, respectively. CONCLUSION: The double-blind randomized clinical trial did not identify a simplified, successful once daily H. pylori treatment for children and adolescents. Thus, twice daily proton pump inhibitor (PPI)-based triple therapies for 7 days remain as the choice of treatment in children. Further, powerful and controlled studies are needed to elucidate the best treatment strategies for H. pylori eradication in this age group.
Asunto(s)
Quimioterapia Combinada/administración & dosificación , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Omeprazol/análogos & derivados , Omeprazol/administración & dosificación , Inhibidores de la Bomba de Protones , 2-Piridinilmetilsulfinilbencimidazoles , Adolescente , Adulto , Azitromicina/administración & dosificación , Pruebas Respiratorias , Niño , Método Doble Ciego , Esquema de Medicación , Resistencia a Medicamentos , Femenino , Humanos , Lansoprazol , Masculino , Cooperación del Paciente , Tinidazol/administración & dosificación , Resultado del TratamientoRESUMEN
BACKGROUND: Antibodies from hyperimmune bovine colostrum have been shown to be effective in treatment against a variety of microorganisms, including Helicobacter pylori in adults. AIM: To test this form of treatment in a small group of H. pylori infected children in a periurban community in Bangladesh. METHODS: Twenty-four infants, 4-29 months old (mean age 16.5+/-7.7 months) and infected with H. pylori, were treated with purified immunoglobulins from hyperimmune bovine colostrum for 1 month, in a placebo-controlled, double-blind pilot study. Diagnosis was established with 13C-urea breath test (UBT) before and after the treatment period and at a 1-month follow-up. RESULTS: None of the hyperimmune bovine colostrum-treated children became UBT negative. Five children initially positive in the UBT screening spontaneously became negative by the start of the study with hyperimmune bovine colostrum/placebo. At the end of the 1-month study period, three had became positive again. CONCLUSION: Hyperimmune bovine colostrum does not eradicate H. pylori infection in infants. Transient H. pylori infection is common among infants in high endemic areas, as is reinfection after clearance. This presents obstacles to evaluation of therapeutic investigations in young children in areas where H. pylori is prevalent.
Asunto(s)
Calostro/inmunología , Infecciones por Helicobacter/terapia , Helicobacter pylori , Inmunización Pasiva , Animales , Bangladesh , Pruebas Respiratorias , Bovinos , Preescolar , Método Doble Ciego , Femenino , Infecciones por Helicobacter/microbiología , Humanos , Lactante , Proyectos Piloto , Embarazo , Población Rural , UreaRESUMEN
BACKGROUND: Oral ingestion of immunoglobulins in humans has been shown to be effective as prophylaxis against enteric infections. However, its therapeutic effect in children with infectious diarrhea has hitherto not been proven. We treated children with rotavirus diarrhea with immunoglobulins extracted from immunized bovine colostrum (IIBC) containing high titers of antibodies against four rotavirus serotypes. METHODS: In this double blind placebo-controlled trial, 80 children with rotavirus diarrhea were randomly assigned to receive orally either 10 g of IIBC (containing 3.6 g of antirotavirus antibodies) daily for 4 days or the same amount of a placebo preparation. The daily stool output (grams/kg/day), intake of oral rehydration solution (ml/kg/day), stool frequency (number of stools/day) and presence of rotavirus in stool were monitored for the 4 days during treatment. RESULTS: Children who received IIBC had significantly less daily and total stool output and stool frequency and required a smaller amount of oral rehydration solution than did children who received placebo (P < 0.05). Clearance of rotavirus from the stool was also earlier in the IIBC group compared with the placebo group (mean day, 1.5 vs. 2.9, P < 0.001). No adverse reactions from the colostrum treatment were observed. CONCLUSIONS: Treatment with antirotavirus immunoglobulin of bovine colostral origin is effective in the management of children with acute rotavirus diarrhea.
Asunto(s)
Diarrea Infantil/tratamiento farmacológico , Inmunoglobulinas/administración & dosificación , Infecciones por Rotavirus/tratamiento farmacológico , Administración Oral , Animales , Anticuerpos Antivirales/inmunología , Bovinos , Preescolar , Calostro/inmunología , Diarrea Infantil/virología , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , India , Lactante , Masculino , Pronóstico , Infecciones por Rotavirus/diagnóstico , Estadísticas no Paramétricas , Resultado del TratamientoRESUMEN
Percutaneous endoscopic gastrostomy (PEG) has gained great popularity for children with malnutrition and eating disorders secondary to chronic illness. However, the procedure is not without risks. We report on 62 infants and children, median age 4 years (1 month-20 years), who underwent PEG placement. Cerebral palsy with or without mental retardation was the most common diagnosis (50%). No complications related to the PEG procedure itself occurred, but postoperative pneumonia was seen in 10%. Late complications were few: intraperitoneal migration of the button in one child and prolapse of the stoma in another. At the time of button placement, after median 14 weeks, mean weight had increased from a standard deviation score of -2.7 to -2.2 (P < 0.001). We consider PEG to be a safe procedure for children with malnutrition requiring enteral feeding. Due to potential risks and complications related to this method, a multidisciplinary approach, as found in a "nutritional support team", is recommended.
Asunto(s)
Endoscopía Gastrointestinal/métodos , Nutrición Enteral/métodos , Trastornos de Alimentación y de la Ingestión de Alimentos/cirugía , Gastrostomía/métodos , Trastornos Nutricionales/cirugía , Adolescente , Profilaxis Antibiótica , Niño , Fenómenos Fisiológicos Nutricionales Infantiles , Preescolar , Endoscopía Gastrointestinal/efectos adversos , Nutrición Enteral/efectos adversos , Nutrición Enteral/economía , Trastornos de Alimentación y de la Ingestión de Alimentos/dietoterapia , Estudios de Seguimiento , Gastrostomía/efectos adversos , Gastrostomía/economía , Humanos , Lactante , Fenómenos Fisiológicos Nutricionales del Lactante , Complicaciones Intraoperatorias/diagnóstico , Complicaciones Intraoperatorias/fisiopatología , Trastornos Nutricionales/dietoterapia , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/fisiopatologíaAsunto(s)
Dolor Abdominal/microbiología , Infecciones por Helicobacter , Helicobacter pylori , Dolor Abdominal/diagnóstico , Dolor Abdominal/tratamiento farmacológico , Niño , Conferencias de Consenso como Asunto , Endoscopía Gastrointestinal , Europa (Continente) , Enfermedades Gastrointestinales/diagnóstico , Enfermedades Gastrointestinales/microbiología , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Helicobacter pylori/aislamiento & purificación , Humanos , Guías de Práctica Clínica como Asunto , SueciaRESUMEN
BACKGROUND: The purpose of the study was to collect data on granulocyte-monocyte adsorptive apheresis (GMA) for the treatment of corticosteroid-dependent (SD) or corticosteroid-resistant (SR) inflammatory bowel disease (IBD) in children from 3 Nordic countries to evaluate its efficacy and safety and to assess practical issues. METHODS: Retrospective data on 37 children treated with GMA were collected. In all, 22 children had ulcerative colitis (UC), 13 Crohn's disease (CD), and 2 had indeterminate colitis (IC). Their mean age was 13.2 years, range 5-17 years, and mean duration of disease was 2.4 years, range 1 month to 6 years. Indication for treatment in the UC group was SD in 11 cases, SR in 6 cases, and other reasons in 5 cases. The corresponding numbers in the CD group were SD in 8 cases, SR in 2 cases, and other reasons in 3 cases. In the IC group, 1 had SD and 1 was refractory to steroids, azathioprine, and infliximab. Efficacy was evaluated by severity indices: the Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn's Disease Activity Index (PCDAI) and tapering of corticosteroids. RESULTS: PUCAI and PCDAI decreased significantly in both groups after 3 months (P = 0.0007, P = 0.025). The dosage of corticosteroid was significantly reduced in the UC group by the end of GMA (P = 0.004) and this response continued after 3 months. Relapse was seen in 2 patients with UC and 3 patients with CD after 3 months follow-up. CONCLUSIONS: GMA seems to be an effective and safe treatment in 81% of the SD or SR pediatric IBD patients, especially in those with UC.
Asunto(s)
Eliminación de Componentes Sanguíneos/métodos , Colitis Ulcerosa/inmunología , Colitis Ulcerosa/terapia , Enfermedad de Crohn/inmunología , Enfermedad de Crohn/terapia , Adolescente , Corticoesteroides/uso terapéutico , Eliminación de Componentes Sanguíneos/efectos adversos , Niño , Colitis Ulcerosa/tratamiento farmacológico , Terapia Combinada , Enfermedad de Crohn/tratamiento farmacológico , Resistencia a Medicamentos , Femenino , Estudios de Seguimiento , Granulocitos , Humanos , Inmunosupresores/uso terapéutico , Masculino , Monocitos , Cooperación del Paciente , Recurrencia , Inducción de Remisión , Estudios RetrospectivosRESUMEN
AIM: To prospectively assess the antibacterial resistance rate in Helicobacter pylori strains obtained from symptomatic children in Europe. METHODS: During a 4-year period, 17 paediatric centres from 14 European countries reported prospectively on patients infected with H pylori, for whom antibiotic susceptibility was tested. RESULTS: A total of 1233 patients were reported from Northern (3%), Western (70%), Eastern (9%) and Southern Europe (18%); 41% originated from outside Europe as indicated by mother's birth-country; 13% were <6 years of age, 43% 6-11 years of age and 44% >11 years of age. Testing was carried out before the first treatment (group A, n = 1037), and after treatment failure (group B, n = 196). Overall resistance to clarithromycin was detected in 24% (mean, A: 20%, B: 42%). The primary clarithromycin resistance rate was higher in boys (odds ratio (OR) 1.58; 1.12 to 2.24, p = 0.01), in children <6 years compared with >12 years (OR 1.82, 1.10 to 3.03, p = 0.020) and in patients living in Southern Europe compared with those living in Northern Europe (OR 2.25; 1.52 to 3.30, p<0.001). Overall resistance rate to metronidazole was 25% (A: 23%, B: 35%) and higher in children born outside Europe (A: adjusted. OR 2.42, 95% CI: 1.61 to 3.66, p<0.001). Resistance to both antibiotics occurred in 6.9% (A: 5.3%, B: 15.3%). Resistance to amoxicillin was exceptional (0.6%). Children with peptic ulcer disease (80/1180, 6.8%) were older than patients without ulcer (p = 0.001). CONCLUSION: The primary resistance rate of H pylori strains obtained from unselected children in Europe is high. The use of antibiotics for other indications seems to be the major risk factor for development of primary resistance.
Asunto(s)
Antiinfecciosos/uso terapéutico , Farmacorresistencia Bacteriana , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Adolescente , Distribución por Edad , Amoxicilina/uso terapéutico , Niño , Preescolar , Claritromicina/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Europa (Continente)/epidemiología , Femenino , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/epidemiología , Humanos , Masculino , Metronidazol/uso terapéutico , Úlcera Péptica/complicaciones , Estudios Prospectivos , Distribución por Sexo , Insuficiencia del TratamientoRESUMEN
Zinc normally participates in the stabilization of the chromatin of human spermatozoa, which have a high content of zinc after ejaculation. Sperm chromatin, depleted of zinc with EDTA, regained stability in the detergent SDS after exposure to Cd2+ in vitro. This effect was reversible with EDTA, but albumin could not reverse the stabilization caused by Cd2+ to the same extent as it reversed the stabilization caused by Zn2+.
Asunto(s)
Cadmio/farmacología , Cromatina/efectos de los fármacos , Espermatozoides/efectos de los fármacos , Zinc/fisiología , Ácido Edético , Humanos , Masculino , Dodecil Sulfato de Sodio , Zinc/antagonistas & inhibidoresRESUMEN
BACKGROUND: The efficacy of a 1-week "triple therapy" in children with Helicobacter pylori gastritis and recurrent abdominal pain was studied. The effect of treatment was also studied in correlation to recurrent abdominal pain. METHODS: Thirty-two children with recurrent abdominal pain were investigated with H. pylori serology, 13C-urea breath test, and endoscopy. Gastric biopsy specimens were analyzed with a rapid urease test and histopathology. H. pylori-positive children were treated with omeprazole, clarithromycin, and metronidazole for 7 days. The same treatment was repeated for 2 weeks if a urea breath test produced positive results 1 month after the treatment period. If the test results were still positive after treatment, a second endoscopy was performed with culture. RESULTS: Twenty-eight (87.5%) children were urea breath test-negative at follow-up 4 weeks (range, 4-15) after treatment. Another child became H. pylori-negative after a second treatment course. Two of the three children who were still positive after the two treatment periods, showed resistance to metronidazole and clarithromycin. CONCLUSIONS: One-week therapy with omeprazole, clarithromycin and metronidazole is an effective treatment in children with H. pylori infection. Bacterial resistance to clarithromycin and metronidazole must be monitored if treatment fails.
Asunto(s)
Claritromicina/uso terapéutico , Gastritis/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Metronidazol/uso terapéutico , Omeprazol/uso terapéutico , Adolescente , Niño , Preescolar , Claritromicina/administración & dosificación , Quimioterapia Combinada , Femenino , Gastritis/tratamiento farmacológico , Humanos , Masculino , Metronidazol/administración & dosificación , Omeprazol/administración & dosificaciónRESUMEN
BACKGROUND: Hyperimmunized bovine colostrum containing antibodies has been shown to be effective in the treatment of rotavirus diarrhea. Antibodies derived from eggs of immunized hens may be a less expensive and more practical alternative. In this study, children with proven rotavirus diarrhea were treated with immunoglobulin extracted from eggs of chicken immunized with human rotavirus strains. METHODS: In a randomized, double-blind study, 79 children with known rotavirus diarrhea were assigned to receive either 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days (HEY group) or a similar preparation obtained from nonimmunized chicken (placebo group). The daily stool frequency and amount, oral rehydration solution iORS) intake, and presence of rotavirus in the stool were monitored for 4 days. RESULTS: In the HEY-treated group, there was significant reduction in stool output (in grams per kilogram per day; HEY vs. placebo; 87+/-59 vs. 120+/-75, P = 0.03), and significant reduction of ORS intake (in milliliters per kilogram per day) (HEY vs. placebo; 84+/-46 vs. 122+/-72, P = 0.008) on day 1 and clearance of virus on day 4 (HEY vs. placebo; 73% vs. 46%, P = 0.02). There was, however, no difference in diarrheal duration between the groups. CONCLUSIONS: Treatment with HEY against four human rotavirus strains resulted in modest improvement of diarrhea associated with earlier clearance of rotavirus from stools. These results indicate an encouraging role of HEY in the treatment of rotavirus-induced diarrhea in children. Further studies are needed to optimize the dose and neutralization titer and thus improve the efficacy of egg yolk immunoglobulin IgY derived from immunized hens.
Asunto(s)
Diarrea Infantil/terapia , Yema de Huevo/inmunología , Inmunoglobulinas/uso terapéutico , Infecciones por Rotavirus/terapia , Animales , Bangladesh , Pollos , Diarrea Infantil/virología , Método Doble Ciego , Heces/virología , Femenino , Humanos , Inmunoglobulinas/administración & dosificación , Lactante , Masculino , Infecciones por Rotavirus/virología , Resultado del TratamientoRESUMEN
Passive immunity against a variety of respiratory and gastrointestinal pathogens has recently been increasingly used clinically, and oral administration of antibodies of both human and non-human origin has been tried both for prophylaxis and treatment of infections. Although the former type of therapy has been shown to be effective, data on the latter are still scarce. This commentary focuses on recent studies on successful oral therapeutic administration of bovine immunoglobulins.
Asunto(s)
Virus de la Diarrea Viral Bovina/inmunología , Diarrea/prevención & control , Inmunización Pasiva , Rotavirus/inmunología , Animales , Bovinos , Diarrea/tratamiento farmacológico , Diarrea/virología , Virus de la Diarrea Viral Bovina/aislamiento & purificación , Humanos , Inmunoglobulina A/inmunología , Inmunoglobulinas/administración & dosificación , Inmunoglobulinas/uso terapéutico , Infecciones por Rotavirus/prevención & control , Infecciones por Rotavirus/virologíaRESUMEN
The effect of orally administered immunoglobulin (IgAbulin) on chronic non-specific diarrhoea of infancy was studied in seven children, median age 26 (21-36) months and duration of diarrhoea 32 (18-84) weeks. Routine laboratory tests for malabsorption and small bowel biopsies were taken in all children before and after 3 weeks of IgAbulin treatment. The biopsy specimens were analysed with regard to histopathology, electronmicroscopy, immunohistochemistry and microbiology. The number of stools decreased from a median of 4.0 (3.0-5.0) to 1.5 (1.0 3.5) (p < 0.05) stools per day over the study period.
Asunto(s)
Diarrea Infantil/terapia , Inmunoglobulina A/administración & dosificación , Inmunoglobulina G/administración & dosificación , Administración Oral , Preescolar , Enfermedad Crónica , Diarrea Infantil/inmunología , Heces/química , Humanos , Inmunoglobulina A/análisis , Inmunoglobulina G/análisis , Lactante , Absorción Intestinal , Intestinos/microbiología , Intestinos/patología , Estudios ProspectivosRESUMEN
BACKGROUND: Passive immunization with orally administered antibodies against specific pathogens has previously been successfully used therapeutically in both animal and human studies. We employed a similar strategy for experimental treatment of mice infected with the gastric pathogen Helicobacter pylori. METHODS: An anti-H. pylori bovine colostral hyperimmune immunoglobulin preparation (BIC) was generated and its efficacy was tested in different in vitro experiments, such as binding to the Lewis(b) blood group antigen, inhibition of adherence of H. pylori to human gastric mucosa tissue sections in situ and in a haemagglutination assay. The BIC preparation was also given in the drinking water to H. pylori-infected mice. RESULTS: An inhibition of 95% of the binding of H. pylori to Lewis(b) glycoconjugate was observed in vitro. Furthermore, a blocking activity of almost 90% was observed when the BIC was preincubated with H. pylori bacteria. Finally, the BIC preparation inhibited the haemagglutination of H. pylori and human red blood cells. Seven of 40 (17.5%) mice remained infected in the treatment group as compared with 25 of 45 (55.5%) in the control group. Hence, the cure rate was 66%, P = < 0.001. The mean number of colonies in the antibody-treated mice where eradication was not successful was also reduced (P < 0.05). In trials using FVB/N transgenic Lewis(b) expressing mice, a cure rate of 50%-66% was observed. CONCLUSION: Bovine colostral antibodies against H. pylori can be generated in high titres, inhibit binding in vitro and can eradicate or reduce the number of bacteria in infected mice.
Asunto(s)
Infecciones por Helicobacter/terapia , Helicobacter pylori/inmunología , Inmunización Pasiva , Animales , Bovinos , Calostro/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Infecciones por Helicobacter/inmunología , Pruebas de Hemaglutinación , Humanos , Inmunoterapia , Antígenos del Grupo Sanguíneo de Lewis/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos , EmbarazoRESUMEN
BACKGROUND: Serologic methods to detect Helicobacter pylori in infants, especially in developing countries, may be limited because of decreased immune response caused by malnutrition. The true prevalence may therefore be underestimated in this age group. Urea breath test is considered to be a good screening method in children but is expensive and therefore is not suitable for screening in developing countries. Simple, inexpensive, and accurate noninvasive methods to detect H. pylori in infants and young children are needed. METHODS: Enzyme immunoassay (EIA) and immunoblot (IB) serologic analyses, 13C-urea breath test (UBT), and immunomagnetic separation--polymerase chain reaction (IMS-PCR) were performed on stool specimens, to detect H. pylori in 68 children between 4 and 24 months of age (mean, 11.5 months) in an endemic area in Bangladesh and the results compared. RESULTS: The occurrence of H. pylori was 57% (n=39) using only UBT, 60% (n=41) using only IMS-PCR, and 78% (n=53) using UBT and IMS-PCR together. The concordance between UBT and IMS-PCR results was 62%. Immunoblot was positive in only 9% (n=6). Results in all 68 children were negative using EIA. DISCUSSION: The prevalence of H. pylori infection in this periurban community and age group was high. Only serologic methods seem to be unsatisfactory for screening of H. pylori infection in infants and may not reflect the true prevalence. Immunomagnetic separation-PCR is a simple and rapid method for detection of H. pylori in stool and is an attractive method for analysis of colonization in infants. However, it may reflect a different stage of disease than UBT. Further studies are needed to clarify this.
Asunto(s)
Enfermedades Gastrointestinales/microbiología , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Anticuerpos Antibacterianos/sangre , Bangladesh , Pruebas Respiratorias , Isótopos de Carbono , Preescolar , Países en Desarrollo , Heces/microbiología , Femenino , Humanos , Separación Inmunomagnética , Lactante , Masculino , Reacción en Cadena de la Polimerasa , Pruebas Serológicas , Urea/metabolismoRESUMEN
BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) and enteropathogenic Escherichia coli (EPEC) are important causes of diarrhoea in young children and are associated with significant mortality rates. Passive immunization with antibodies from immunized cows has previously been shown to be effective as prophylaxis against E. coli-induced diarrhoea and therapeutically against rotavirus and cryptosporidia-induced diarrhoea. METHODS: We tested the therapeutic efficacy of an oral bovine immunoglobulin milk concentrate (BIC) from cows hyperimmunized with ETEC and EPEC strains, in a randomized, placebo-controlled study in children with E. coli-induced diarrhoea. Eighty-six children between 4-24 months of age attending the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) with E. coli-induced diarrhoea (63 EPEC/ETEC and 23 with other diarrhoeagenic E. coli) were randomly assigned to receive orally administered BIC (20 g) containing anti-ETEC/EPEC antibodies or a placebo preparation daily for 4 consecutive days. Daily stool output, intake of oral rehydration solution (ORS), stool frequency, and presence of diarrhoeagenic E. coli strains in the stool were monitored for 4 days. RESULTS: Children in the treatment group tolerated the BIC with no side effects. There were no significant differences between the two groups with regard to ORS intake, stool output, frequency of diarrhoea, or clearance of pathogen. Nor was there any significant alteration in the duration of diarrhoea. CONCLUSIONS: In contrast to the prophylactic efficacy of anti-E. coli BIC and the therapeutic efficacy of a similarly prepared anti-rotavirus BIC, antibodies from hyperimmunized cows appear to have no significant therapeutic benefit in the treatment of acute diarrhoea due to EPEC/ETEC.